Company Profile
Savara, Inc. Stock Price, News & Analysis
- Ticker:
- SVRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.79 USD (+5.08%)
Close
Last updated: August 6, 2026
1.08B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SVRA closed up 5.08% at $5.79. No new same-company headline was identified in the current news window.
Company overview
Business overview
Savara is a respiratory company focused on rare lung disease and inhaled therapies. Its story is built around severe pulmonary conditions with limited treatment options.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Savara sits in specialty biopharma.
Business Model Characteristics
The company depends on clinical data, inhaled-delivery execution, and the ability to build a rare-respiratory franchise.
Position Within the Biotechnology Landscape
Savara is a niche respiratory biotech whose stock is tightly linked to trial and regulatory progress.
Future catalysts
Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work. The key question is whether the program can keep moving toward a real rare-disease commercial opportunity.
Recent news
- 01
Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Source: Savara, Inc.
- 02
- 03
- 04
Savara Reports Third Quarter 2018 Financial Results and Provides Business Update
Source: Savara, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Savara, Inc. (SVRA)?
Savara, Inc. (SVRA) most recently closed at 5.79 USD, a +5.08% move versus the previous session.
What is the market cap of Savara, Inc. (SVRA)?
Savara, Inc. currently has a market capitalization of 1.08B USD on BioPharmSignal.
What does Savara, Inc. do?
Savara is a respiratory company focused on rare lung disease and inhaled therapies. Its story is built around severe pulmonary conditions with limited treatment options.
On which exchange is SVRA stock listed?
Savara, Inc. (SVRA) is associated with NASDAQ, United States, Biopharma.
What is Savara?
Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work.
Which conditions is Savara, Inc. targeting with Savara?
Savara, Inc. is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Savara, Inc. describe recent progress with Savara?
Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work.
What future catalysts are investors watching for Savara, Inc.?
Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work. The key question is whether the program can keep moving toward a real rare-disease commercial opportunity.